Drugs / K-757
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06305351 | Dec 2023 → May 2024 | obesity disorder, type 2 diabetes mellitus | Kallyope Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05890950 | Mar → Jul 2023 | obesity disorder, type 2 diabetes mellitus | Kallyope Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05900531 | Sep 2022 → May 2023 | obesity disorder | Kallyope Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06019559 | Sep 2023 → Feb 2024 | obesity disorder | Kallyope Inc. | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K-757 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06305351 ↗ |
| Route | Oral | “Both administered orally” NCT05890950 ↗ |